Business Wire

Torq Lands Virgin Atlantic CISO John White to Lead Enterprise Shift to Agentic AI

4.2.2026 15:00:00 CET | Business Wire | Press Release

Share

Torq, the established agentic security operations leader, today announced former Virgin Atlantic CISO John White has joined Torq as Field CISO. Following Torq’s $140M Series D, White shifts from the customer side to the Torq leadership team, propelling global enterprise CISOs to modernize their strategies and adopt true Agentic AI.

White is a highly respected security executive with more than 20 years of leadership experience. Prior to Virgin Atlantic, he built and transformed security functions for global organizations including ASOS, Liberty Global, AEG Europe, and KPMG, spanning retail, telecommunications, energy, and live entertainment.

At Virgin Atlantic, White did not just oversee security, he reinvented it. Leading a multi-year transformation across airline, cargo, and vacation businesses, White deployed the Torq AI SOC Platform to modernize its cyber operations. The result was a dramatic increase in protection and efficiency that convinced him the industry had reached a pivotal moment.

“I’m thrilled to join Torq as agentic SOC innovation meets market momentum at hyperscale,” said White. “Having seen firsthand how the Torq AI SOC Platform accelerates triage, investigation, and response across complex IT environments, I’m excited to help lead Torq customers and prospects into this incredible new era. The Torq AI SOC Platform proves AI is no longer optional. Instead of creating conventional org charts, I encourage CISOs everywhere to put up an agentic workforce chart and ensure their SOC team is aligned with its capabilities and potential. It’s official: Agentic AI is now the core architecture of the modern SOC.”

As a strategic partner for security leaders In his new role, White serves as a consultative peer to Torq’s community of CISOs and security stakeholders. He focuses on CISO-to-CISO engagement, helping security teams cut through the noise of the market, and implement practical, outcome-driven Agentic AI strategies. His mandate is to bridge the gap between technical potential and executive strategy for Torq’s customer base, which includes Marriott, PepsiCo, Procter & Gamble, Siemens, and Uber.

“Bringing John White on board reflects our commitment to a practitioner-led approach,” said Ofer Smadari, CEO and co-founder, Torq. “John isn’t a theorist. Rather, he has the battle scars from running mission-critical security at a global airline. He understands the pressure CISOs face because he was in their seat just yesterday. He chose to join Torq to help the industry move faster, and his experience will be invaluable to every security leader looking to fix their SOC.”

About Torq

Torq is transforming cybersecurity with the Torq AI SOC platform. Torq empowers enterprises to instantly and precisely detect and respond to security events at scale. Torq’s customer base includes major multinational enterprise customers, including Abnormal Security, Armis, Check Point Security, Chipotle Mexican Grill, Inditex (Zara, Bershka, and Pull & Bear), Informatica, Kyocera, PepsiCo, Procter & Gamble, Siemens, Telefónica, Valvoline, Virgin Atlantic, and Wiz.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260204167249/en/

Contacts

Media Contact
torq@teamhighwire.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye